Calcitonin gene related peptide in migraine: Current therapeutics, future implications and potential off-target effects
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Accepteret manuskript, 343 KB, PDF-dokument
Migraine is the second largest cause of years lost to disability globally among all diseases, with a worldwide prevalence over 1 billion. Despite the global burden of migraine, few classes of therapeutics have been specifically developed to combat migraine. After 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine. Like all new therapeutics; however, we have limited real-world experience and CGRP has several known systemic actions that warrant consideration. This article provides a narrative review of the evidence for CGRP antagonists and summarises the known and potential side effects that should be considered.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Journal of Neurology, Neurosurgery and Psychiatry |
Vol/bind | 92 |
Udgave nummer | 12 |
Sider (fra-til) | 1325-1334 |
ISSN | 0022-3050 |
DOI | |
Status | Udgivet - 2021 |
Bibliografisk note
Publisher Copyright:
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
ID: 276702337